SCHEMBL24150529

SCHEMBL24150529

C=CC(=O)Nc1cccc(-c2ccc3nccc(NC(=O)c4ccco4)c3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.53
▸ KDM4E B2RXH2 7/20 0.50
▸ ALDH1A1 P00352 5/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ PLCG1 P19174 4/20 0.49
▸ MAPT P10636 5/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ HTT P42858 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ PTPN1 P18031 1/20 0.47
▸ PTPN11 Q06124 1/20 0.47
▸ USP2 O75604 2/20 0.47
▸ JAK3 P52333 1/20 0.46
▸ TSHR P16473 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30190645 1.00 EGFR (0.53) EGFRKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL24150192 0.84 EGFR (0.59) EGFRPLCG1MEN1KMT2APTPN1
SCHEMBL30190503 0.84 EGFR (0.59) EGFRPLCG1MEN1KMT2APTPN1
SCHEMBL24150583 0.83 EGFR (0.60) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL24150536 0.82 EGFR (0.52) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL24150528 0.82 CYP1A2 (0.54) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL30191312 0.82 EGFR (0.67) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL24150981 0.82 EGFR (0.67) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL24150175 0.80 EGFR (0.57) EGFRPLCG1PTPN1PTPN11JAK3
SCHEMBL24150178 0.79 PLCG1 (0.57) EGFRPLCG1PTPN1PTPN11JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
WO-2021262596-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS EGFR 888/4885KDM4E 3236/4885ALDH1A1 2214/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS EGFR 888/4885KDM4E 3236/4885ALDH1A1 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback